EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human

Jingyi Gong, Tomas G Neilan, Daniel A Zlotoff iD

Immunological Reviews · 2023

DOI: 10.1111/imr.13240 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2023. Verfasst von Jingyi Gong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Myocarditis, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The broad application of immune checkpoint inhibitors (ICIs) has led to significant gains in cancer outcomes. By abrogating inhibitory signals, ICIs promote T cell targeting of cancer cells but can frequently trigger autoimmune manifestations, termed immune‐related adverse events (irAEs), affecting essentially any organ system. Among cardiovascular irAEs, immune‐related myocarditis (irMyocarditis) is the most described and carries the highest morbidity. The currently recommended treatment for irMyocarditis is potent immunosuppression with corticosteroids and other agents, but this has limited evidence basis. The cellular pathophysiology of irMyocarditis remains poorly understood, though mouse models and human data have both implicated effector CD8 + T cells, some of which are specific for the cardiomyocyte protein α‐myosin. While the driving molecular signals and transcriptional programs are not well defined, the involvement of chemokine receptors such as CCR5 and CXCR3 has been proposed. Fundamental questions regarding why only approximately 1% of ICI recipients develop irMyocarditis and why irMyocarditis carries a much worse prognosis than other forms of lymphocytic myocarditis remain unanswered. Further work in both murine systems and with human samples are needed to identify better tools for diagnosis, risk‐stratification, and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisNeoplasmsHumansAnimalsMiceImmune Checkpoint InhibitorsCD8-Positive T-LymphocytesImmunosuppression Therapy

Stichwörter der Autor:innen

cardio-oncologyimmune checkpoint inhibitorsimmune-related adverse eventsmyocarditis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Daniel A Zlotoff

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Gong, J., Neilan, T. G., & Zlotoff, D. A. (2023). Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human. Immunological Reviews. https://doi.org/10.1111/imr.13240

Vancouver

Gong J, Neilan TG, Zlotoff DA. Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human. Immunological Reviews. 2023. doi:10.1111/imr.13240

BibTeX
@article{Gong2023,
  author = {Gong, Jingyi and Neilan, Tomas G and Zlotoff, Daniel A},
  title = {Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human},
  journal = {Immunological Reviews},
  year = {2023},
  doi = {10.1111/imr.13240}
}
Kostenlos starten →